Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Becotatug Vedotin, Tislelizumab, and Lenvatinib in Advanced ESCC
NCT07686926Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Aug 2026
- Primary completion
- Jul 2028
01
Overview
A Phase 2 trial of becotatug vedotin in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
becotatug vedotin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07686926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07686926.